Table 2.
Most altered genes among representative cancers in our cohort (number of patients, along with genetic alterations and frequency).
| Cancer type | Genes | Nb | Freq. (%) | Cancer type | Genes | Nb | Freq. (%) |
|---|---|---|---|---|---|---|---|
| Glioma (n=33) | TP53 | 8 | 24 | Prostate (n=10) | TP53 | 6 | 60 |
| TERT | 8 | 24 | AR | 4 | 40 | ||
| PTEN | 7 | 21 | Pancreatic (n=8) | CTNNB1 | 2 | 25 | |
| NF1 | 6 | 18 | KRAS | 2 | 25 | ||
| EGFR | 5 | 15 | SMAD4 | 2 | 25 | ||
| Lung (n=27) | TP53 | 14 | 52 | TP53 | 2 | 25 | |
| KRAS | 4 | 15 | Ovarian (n=7) | TP53 | 6 | 86 | |
| Breast (n=25) | PIK3CA | 9 | 36 | PIK3R1 | 2 | 29 | |
| ESR1 | 7 | 28 | Head & Neck (n=6) | TP53 | 3 | 50 | |
| C11orf30 (EMSY) | 6 | 24 | CCND1 | 2 | 33 | ||
| TP53 | 6 | 24 | CDKN2A/B | 2 | 33 | ||
| CCND1 | 5 | 20 | DNMT3A | 2 | 33 | ||
| FGF19 | 5 | 20 | FGF19 | 2 | 33 | ||
| FGF3 | 5 | 20 | FGF3 | 2 | 33 | ||
| FGF4 | 5 | 20 | TERT | 2 | 33 | ||
| FGFR1 | 5 | 20 | Gastric (n=5) | TP53 | 3 | 60 | |
| ZNF703 | 5 | 20 | ARID1A | 2 | 40 | ||
| CDH1 | 4 | 16 | ATM | 2 | 40 | ||
| NSD3 (WHSC1L1) | 4 | 16 | CDKN2A/B | 2 | 40 | ||
| Colorectal (n=10) | TP53 | 8 | 80 | PIK3CA | 2 | 40 | |
| APC | 6 | 60 | |||||
| KRAS | 3 | 30 | |||||
| SMAD4 | 3 | 30 |
Cancers for which more than five patients had available sequencing results were analyzed. Genes with class 4-5 variants in at least four patients with the most represented cancers (glioma, lung, and breast cancers), and those with class 4-5 variants in at least two patients with the least frequent cancers (colorectal, prostate, pancreatic, ovarian, head and neck, and gastric cancers), were selected for the global cohort. Abbreviations: Nb., number of patients with genetic alterations; Freq., frequency (in %).